Analysis | Metabolite Name | Measured Value | Units | CASE_CONTROL | Chemotherapy | Drug | Race | TIMEPOINT | Tamoxyfen | Taxane |
---|---|---|---|---|---|---|---|---|---|---|
Reversed phase POSITIVE ION MODE | SARCOSINE (CAS# 107-97-1); (M+H)+ | 1415 | Peak area | Case | N | Letrozole | White | 3 Month | N | N |
Reversed phase POSITIVE ION MODE | SARCOSINE (CAS# 107-97-1); (M+H)+ | 1568 | Peak area | Control | Y | Exemestane | White | Baseline | N | N |
Reversed phase POSITIVE ION MODE | SARCOSINE (CAS# 107-97-1); (M+H)+ | 1930 | Peak area | Control | N | Exemestane | White | 3 Month | N | N |
Reversed phase POSITIVE ION MODE | SARCOSINE (CAS# 107-97-1); (M+H)+ | 3177 | Peak area | Case | N | Letrozole | White | 3 Month | Y | N |
Reversed phase POSITIVE ION MODE | SARCOSINE (CAS# 107-97-1); (M+H)+ | 3876 | Peak area | Case | N | Letrozole | White | Baseline | N | N |
Reversed phase POSITIVE ION MODE | SARCOSINE (CAS# 107-97-1); (M+H)+ | 4383 | Peak area | Case | Y | Letrozole | White | 3 Month | Y | Y |
Reversed phase POSITIVE ION MODE | SARCOSINE (CAS# 107-97-1); (M+H)+ | 5215 | Peak area | Case | N | Exemestane | White | 3 Month | Y | N |
Reversed phase POSITIVE ION MODE | SARCOSINE (CAS# 107-97-1); (M+H)+ | 5557 | Peak area | Control | Y | Exemestane | White | 3 Month | N | N |
Reversed phase POSITIVE ION MODE | SARCOSINE (CAS# 107-97-1); (M+H)+ | 6376 | Peak area | Case | Y | Exemestane | White | Baseline | Y | N |
Reversed phase POSITIVE ION MODE | SARCOSINE (CAS# 107-97-1); (M+H)+ | 8529 | Peak area | Control | Y | Exemestane | White | 3 Month | N | Y |
Reversed phase POSITIVE ION MODE | SARCOSINE (CAS# 107-97-1); (M+H)+ | 8791 | Peak area | Control | Y | Exemestane | White | 3 Month | N | Y |
Reversed phase POSITIVE ION MODE | SARCOSINE (CAS# 107-97-1); (M+H)+ | 9217 | Peak area | Case | Y | Exemestane | White | Baseline | Y | Y |
Reversed phase POSITIVE ION MODE | SARCOSINE (CAS# 107-97-1); (M+H)+ | Peak area | Case | N | Exemestane | Black | 3 Month | N | N | |
Reversed phase POSITIVE ION MODE | SARCOSINE (CAS# 107-97-1); (M+H)+ | Peak area | Case | N | Exemestane | Black | Baseline | N | N | |
Reversed phase POSITIVE ION MODE | SARCOSINE (CAS# 107-97-1); (M+H)+ | Peak area | Case | N | Exemestane | White | 3 Month | N | N | |
Reversed phase POSITIVE ION MODE | SARCOSINE (CAS# 107-97-1); (M+H)+ | Peak area | Case | N | Exemestane | White | 3 Month | Y | N | |
Reversed phase POSITIVE ION MODE | SARCOSINE (CAS# 107-97-1); (M+H)+ | Peak area | Case | N | Exemestane | White | Baseline | N | N | |
Reversed phase POSITIVE ION MODE | SARCOSINE (CAS# 107-97-1); (M+H)+ | Peak area | Case | N | Exemestane | White | Baseline | Y | N | |
Reversed phase POSITIVE ION MODE | SARCOSINE (CAS# 107-97-1); (M+H)+ | Peak area | Case | N | Letrozole | Black | 3 Month | N | N | |
Reversed phase POSITIVE ION MODE | SARCOSINE (CAS# 107-97-1); (M+H)+ | Peak area | Case | N | Letrozole | Black | Baseline | N | N | |
Reversed phase POSITIVE ION MODE | SARCOSINE (CAS# 107-97-1); (M+H)+ | Peak area | Case | N | Letrozole | White | 3 Month | N | N | |
Reversed phase POSITIVE ION MODE | SARCOSINE (CAS# 107-97-1); (M+H)+ | Peak area | Case | N | Letrozole | White | 3 Month | Y | N | |
Reversed phase POSITIVE ION MODE | SARCOSINE (CAS# 107-97-1); (M+H)+ | Peak area | Case | N | Letrozole | White | Baseline | N | N | |
Reversed phase POSITIVE ION MODE | SARCOSINE (CAS# 107-97-1); (M+H)+ | Peak area | Case | N | Letrozole | White | Baseline | Y | N | |
Reversed phase POSITIVE ION MODE | SARCOSINE (CAS# 107-97-1); (M+H)+ | Peak area | Case | Y | Exemestane | Black | 3 Month | N | Y | |
Reversed phase POSITIVE ION MODE | SARCOSINE (CAS# 107-97-1); (M+H)+ | Peak area | Case | Y | Exemestane | Black | Baseline | N | Y | |
Reversed phase POSITIVE ION MODE | SARCOSINE (CAS# 107-97-1); (M+H)+ | Peak area | Case | Y | Exemestane | White | 3 Month | N | Y | |
Reversed phase POSITIVE ION MODE | SARCOSINE (CAS# 107-97-1); (M+H)+ | Peak area | Case | Y | Exemestane | White | 3 Month | Y | N | |
Reversed phase POSITIVE ION MODE | SARCOSINE (CAS# 107-97-1); (M+H)+ | Peak area | Case | Y | Exemestane | White | 3 Month | Y | Y | |
Reversed phase POSITIVE ION MODE | SARCOSINE (CAS# 107-97-1); (M+H)+ | Peak area | Case | Y | Exemestane | White | Baseline | N | Y | |
Reversed phase POSITIVE ION MODE | SARCOSINE (CAS# 107-97-1); (M+H)+ | Peak area | Case | Y | Exemestane | White | Baseline | Y | N | |
Reversed phase POSITIVE ION MODE | SARCOSINE (CAS# 107-97-1); (M+H)+ | Peak area | Case | Y | Exemestane | White | Baseline | Y | Y | |
Reversed phase POSITIVE ION MODE | SARCOSINE (CAS# 107-97-1); (M+H)+ | Peak area | Case | Y | Letrozole | White | 3 Month | Y | Y | |
Reversed phase POSITIVE ION MODE | SARCOSINE (CAS# 107-97-1); (M+H)+ | Peak area | Case | Y | Letrozole | White | Baseline | Y | Y | |
Reversed phase POSITIVE ION MODE | SARCOSINE (CAS# 107-97-1); (M+H)+ | Peak area | Control | N | Exemestane | Black | 3 Month | Y | N | |
Reversed phase POSITIVE ION MODE | SARCOSINE (CAS# 107-97-1); (M+H)+ | Peak area | Control | N | Exemestane | Black | Baseline | Y | N | |
Reversed phase POSITIVE ION MODE | SARCOSINE (CAS# 107-97-1); (M+H)+ | Peak area | Control | N | Exemestane | White | 3 Month | N | N | |
Reversed phase POSITIVE ION MODE | SARCOSINE (CAS# 107-97-1); (M+H)+ | Peak area | Control | N | Exemestane | White | 3 Month | Y | N | |
Reversed phase POSITIVE ION MODE | SARCOSINE (CAS# 107-97-1); (M+H)+ | Peak area | Control | N | Exemestane | White | Baseline | N | N | |
Reversed phase POSITIVE ION MODE | SARCOSINE (CAS# 107-97-1); (M+H)+ | Peak area | Control | N | Exemestane | White | Baseline | Y | N | |
Reversed phase POSITIVE ION MODE | SARCOSINE (CAS# 107-97-1); (M+H)+ | Peak area | Control | N | Letrozole | Black | 3 Month | N | N | |
Reversed phase POSITIVE ION MODE | SARCOSINE (CAS# 107-97-1); (M+H)+ | Peak area | Control | N | Letrozole | Black | Baseline | N | N | |
Reversed phase POSITIVE ION MODE | SARCOSINE (CAS# 107-97-1); (M+H)+ | Peak area | Control | N | Letrozole | White | 3 Month | N | N | |
Reversed phase POSITIVE ION MODE | SARCOSINE (CAS# 107-97-1); (M+H)+ | Peak area | Control | N | Letrozole | White | 3 Month | Y | N | |
Reversed phase POSITIVE ION MODE | SARCOSINE (CAS# 107-97-1); (M+H)+ | Peak area | Control | N | Letrozole | White | Baseline | N | N | |
Reversed phase POSITIVE ION MODE | SARCOSINE (CAS# 107-97-1); (M+H)+ | Peak area | Control | N | Letrozole | White | Baseline | Y | N | |
Reversed phase POSITIVE ION MODE | SARCOSINE (CAS# 107-97-1); (M+H)+ | Peak area | Control | Y | Exemestane | White | 3 Month | N | N | |
Reversed phase POSITIVE ION MODE | SARCOSINE (CAS# 107-97-1); (M+H)+ | Peak area | Control | Y | Exemestane | White | 3 Month | Y | N | |
Reversed phase POSITIVE ION MODE | SARCOSINE (CAS# 107-97-1); (M+H)+ | Peak area | Control | Y | Exemestane | White | 3 Month | Y | Y | |
Reversed phase POSITIVE ION MODE | SARCOSINE (CAS# 107-97-1); (M+H)+ | Peak area | Control | Y | Exemestane | White | Baseline | N | N | |
Reversed phase POSITIVE ION MODE | SARCOSINE (CAS# 107-97-1); (M+H)+ | Peak area | Control | Y | Exemestane | White | Baseline | N | Y | |
Reversed phase POSITIVE ION MODE | SARCOSINE (CAS# 107-97-1); (M+H)+ | Peak area | Control | Y | Exemestane | White | Baseline | Y | N | |
Reversed phase POSITIVE ION MODE | SARCOSINE (CAS# 107-97-1); (M+H)+ | Peak area | Control | Y | Exemestane | White | Baseline | Y | Y | |
Reversed phase POSITIVE ION MODE | SARCOSINE (CAS# 107-97-1); (M+H)+ | Peak area | Control | Y | Letrozole | White | 3 Month | Y | N | |
Reversed phase POSITIVE ION MODE | SARCOSINE (CAS# 107-97-1); (M+H)+ | Peak area | Control | Y | Letrozole | White | 3 Month | Y | Y | |
Reversed phase POSITIVE ION MODE | SARCOSINE (CAS# 107-97-1); (M+H)+ | Peak area | Control | Y | Letrozole | White | Baseline | Y | N | |
Reversed phase POSITIVE ION MODE | SARCOSINE (CAS# 107-97-1); (M+H)+ | Peak area | Control | Y | Letrozole | White | Baseline | Y | Y |